Stock PRQR PROQR THERAPEUTICS N.V.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report

ProQR Therapeutics N.V. Stock price

Equities

PRQR

NL0010872495

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 10:40:55 2023-10-02 am EDT 		Intraday chart for ProQR Therapeutics N.V. 5-day change 1st Jan Change
1.280 USD -1.54% -11.72% -65.41%
Sep. 27 ProQR Therapeutics Says Sale of Ophthalmic Assets to Laboratoires Thea Terminated MT
Sep. 27 Laboratoires Théa S.A.S. cancelled the acquisition of Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V.. CI

Financials (USD)

Sales 2023 * 20 M Sales 2024 * 11 M Capitalization 105 M
Net income 2023 * -20 M Net income 2024 * -31 M EV / Sales 2023 *
-0,52x
Net cash position 2023 * 116 M Net cash position 2024 * 72 M EV / Sales 2024 *
2,91x
P/E ratio 2023 *
-4,04x
P/E ratio 2024 *
-2,98x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float77.65%
More Fundamentals * Assessed data

Chart ProQR Therapeutics N.V.

Dynamic Chart

Latest news about ProQR Therapeutics N.V.

ProQR Therapeutics Says Sale of Ophthalmic Assets to Laboratoires Thea Terminated MT
Laboratoires Théa S.A.S. cancelled the acquisition of Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V.. CI
Citigroup Adjusts ProQR Therapeutics' Price Target to $1.80 From $2.10, Keeps Neutral Rating MT
ProQR Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Laboratoires Théa S.A.S. agreed to acquire Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. for approximately ?135 million. CI
Chardan Assigns New Price Target of $2 to ProQR Therapeutics, Keeps Neutral Rating MT
ProQR Therapeutics N.V. Approves the Appointment of Theresa Heggie and Begoña Carreño as Supervisory Board Member CI
Cantor Fitzgerald Adjusts Price Target on ProQR Therapeutics to $4.50 From $5, Maintains Overweight Rating MT
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
HC Wainwright Raises Price Target on ProQR Therapeutics to $5 From $1.50, Maintains Buy Rating MT
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Transcript : ProQR Therapeutics N.V. - Special Call CI
Proqr Therapeutics N.V. Announces Initial Pipeline Targets and Highlights Axiomer RNA Editing Platform Technology At R&D Event CI
ProQR Therapeutics Wins Hearing on Key Patent for Axiomer MT
ProQR Therapeutics N.V. Announces Successful Defense of Key Axiomer(R) Patent Protecting Adar-Mediated RNA Editing CI
More news

Analyst Recommendations on ProQR Therapeutics N.V.

Citigroup Adjusts ProQR Therapeutics' Price Target to $1.80 From $2.10, Keeps Neutral Rating MT
Chardan Assigns New Price Target of $2 to ProQR Therapeutics, Keeps Neutral Rating MT
Cantor Fitzgerald Adjusts Price Target on ProQR Therapeutics to $4.50 From $5, Maintains Overweight Rating MT
HC Wainwright Raises Price Target on ProQR Therapeutics to $5 From $1.50, Maintains Buy Rating MT
Raymond James Adjusts ProQR Therapeutics Price Target to $5 From $2, Maintains Outperform Rating MT
More recommendations

Press releases ProQR Therapeutics N.V.

Stargardt Disease Pipeline, Clinical Trials, Emerging Therapies, and FDA Approvals 2023 (Updated) AQ
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference GL
ProQR Therapeutics Provides Update on Ophthalmic Assets GL
Epidermolysis Bullosa Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated) AQ
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference GL
More press releases

News in other languages on ProQR Therapeutics N.V.

Les Laboratoires Théa S.A.S. ont annulé l'acquisition de Sepofarsen et Ultevursen Ophthalmic Assets de ProQR Therapeutics N.V. (NasdaqCM:PRQR).
ProQR Therapeutics N.V. publie ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2023
ProQR Therapeutics N.V. présente ses résultats pour le premier trimestre clos le 31 mars 2023
ProQR Therapeutics N.V. approuve la nomination de Theresa Heggie et de Begoña Carreño en tant que membres du conseil de surveillance
ProQR Therapeutics N.V. publie ses résultats pour l'exercice clos le 31 décembre 2022
More news

Quotes and Performance

1 day-2.26%
1 week-11.56%
1 month-18.24%
3 months-19.75%
6 months-38.97%
Current year-64.86%
More quotes

Highs and lows

1 week
1.30
Extreme 1.3
1.48
1 month
1.30
Extreme 1.3
1.65
Current year
1.30
Extreme 1.3
3.85
1 year
0.74
Extreme 0.74
3.85
3 years
0.53
Extreme 0.53
9.46
5 years
0.53
Extreme 0.53
24.00
10 years
0.53
Extreme 0.53
27.60
More quotes

Managers and Directors - ProQR Therapeutics N.V.

Managers TitleAgeSince
Gerard J. Platenburg CTO
 Chief Tech/Sci/R&D Officer 59 2021
Daniel Anton de Boer CEO
 Chief Executive Officer 40 2012
Jurriaan Dekkers DFI
 Director of Finance/CFO - 2022
Members of the board TitleAgeSince
James Shannon BRD
 Director/Board Member 67 2016
Domenico Valerio CHM
 Chairman 67 2013
Bart Filius BRD
 Director/Board Member 53 2019
More insiders

Quotes

Date Price Change Volume
23-10-02 1.280 -1.54% 14 950
23-09-29 1.300 -2.26% 167,072
23-09-28 1.330 -3.62% 203,014
23-09-27 1.380 -4.83% 292,133
23-09-26 1.450  0.00% 95,588

Delayed Quote Nasdaq, October 02, 2023 at 09:30 am EDT

More quotes

Company Profile

ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber's congenital amaurosis (LCA).
Sector
Biotechnology & Medical Research
Calendar
09:30am - Chardan Genetic Medicines Conference - Panel
More about the company

Income Statement Evolution

More financial data

Ratings for ProQR Therapeutics N.V.

Trading Rating :
Investor Rating :
ESG Refinitiv :
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.300USD
Average target price
3.757USD
Spread / Average Target
+189.01%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi. (M$)
PROQR THERAPEUTICS N.V. Stock ProQR Therapeutics N.V.
-64.86% 105 M $
VITASPRING BIOMEDICAL CO. LTD. Stock VitaSpring Biomedical Co. Ltd.
+4.17% 3 105 M $
STRUCTURE THERAPEUTICS INC. Stock Structure Therapeutics Inc.
 0.00% 2 232 M $
ADOCIA Stock Adocia
+120.15% 90 M $
OLIPASS CORPORATION Stock OLIPASS Corporation
-47.70% 74 M $
RENOVARO BIOSCIENCES INC. Stock Renovaro Biosciences Inc.
+333.98% 294 M $
PEPTRON, INC. Stock Peptron, Inc.
+339.87% 516 M $
SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. Stock Shanghai Allist Pharmaceuticals Co., Ltd.
+98.48% 2 409 M $
ADC THERAPEUTICS SA Stock ADC Therapeutics SA
-76.64% 72 M $
BIOVIE INC. Stock BioVie Inc.
-56.11% 126 M $
Bio Therapeutic Drugs
  1. Markets
  2. Equities
  3. Stock ProQR Therapeutics N.V. - Nasdaq
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer